In order to enhance the pace of developing new drugs for treatment of brain disorders, prominent drug makers have informed that they will be sharing the information collected from several clinical experiments conducted for Alzheimer's and Parkinson's disease.
The collected data is "public/private partnership information", which was revealed on Friday.
Drug makers claim that the data contains information from about 4,000 patients who were suffering from neurodegenerative diseases.
This collective information is better than keeping parts of it with Company separately, as it will help in jointly researching the reasons and variations in the diseases.
The supporters of this joint data opine that this will initiate some new researches for combating common brain disorders.
Scientists and researchers have been trying hard since years to find out effectual treatment for Alzheimer's disease, but nothing as impactful has been discovered yet.
It is known that more than 26 million people suffer from Alzheimer's disease every year and it is also the most widespread form of dementia.
Also, about four million people globally are affected by Parkinson's disease.
President and Chief Executive of the Critical Path Institute, Dr. Raymond Woosley said that the released database will assist the scientists and the drug makers in designing more efficient clinical trials of potential treatments.